AR030516A1 - Uso de una combinacion de salmeterol y fluticasona - Google Patents

Uso de una combinacion de salmeterol y fluticasona

Info

Publication number
AR030516A1
AR030516A1 ARP010104122A ARP010104122A AR030516A1 AR 030516 A1 AR030516 A1 AR 030516A1 AR P010104122 A ARP010104122 A AR P010104122A AR P010104122 A ARP010104122 A AR P010104122A AR 030516 A1 AR030516 A1 AR 030516A1
Authority
AR
Argentina
Prior art keywords
salmeterol
fluticasona
combination
combinations
refers
Prior art date
Application number
ARP010104122A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR030516A1 publication Critical patent/AR030516A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatment Of Water By Ion Exchange (AREA)

Abstract

Se refiere al uso de las combinaciones del salmeterol y propionato de fluticasona para el tratamiento de la enfermedad pulmonar obstructiva cronica.
ARP010104122A 2000-08-31 2001-08-29 Uso de una combinacion de salmeterol y fluticasona AR030516A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22938100P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
AR030516A1 true AR030516A1 (es) 2003-08-20

Family

ID=22860986

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104122A AR030516A1 (es) 2000-08-31 2001-08-29 Uso de una combinacion de salmeterol y fluticasona

Country Status (24)

Country Link
US (1) US20040009963A1 (es)
EP (1) EP1313484A2 (es)
JP (1) JP2004507494A (es)
KR (1) KR20030031997A (es)
CN (1) CN1449288A (es)
AP (1) AP2003002753A0 (es)
AR (1) AR030516A1 (es)
AU (1) AU2001284236A1 (es)
BG (1) BG107596A (es)
BR (1) BR0113555A (es)
CA (1) CA2420532A1 (es)
EA (1) EA200300152A1 (es)
EC (1) ECSP034487A (es)
HU (1) HUP0303755A2 (es)
IL (1) IL154403A0 (es)
MA (1) MA25834A1 (es)
MX (1) MXPA03001752A (es)
NO (1) NO20030899L (es)
OA (1) OA12370A (es)
PE (1) PE20020387A1 (es)
PL (1) PL365582A1 (es)
SK (1) SK2302003A3 (es)
WO (1) WO2002017894A2 (es)
ZA (1) ZA200301475B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
ES2471139T3 (es) * 2003-08-06 2014-06-25 Galephar M/F Combinaciones ventajosas para la inhalaci�n de nacistelina y broncodilatadores
TR200907913A2 (tr) * 2009-10-20 2011-05-23 Bi̇lgi̇ç Mahmut İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR201000681A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
TR200909791A2 (tr) * 2009-12-25 2011-07-21 B�Lg�� Mahmut Salmeterol ve flutikazon içeren farmasötik bileşim@
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007781A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
EP2991625A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024033625A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Plc Ensifentrine (rpl-554) for increasing trough lung function
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9924992D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.

Also Published As

Publication number Publication date
IL154403A0 (en) 2003-09-17
MA25834A1 (fr) 2003-07-01
CA2420532A1 (en) 2002-03-07
BG107596A (bg) 2004-01-30
KR20030031997A (ko) 2003-04-23
WO2002017894A3 (en) 2002-08-08
EP1313484A2 (en) 2003-05-28
AU2001284236A1 (en) 2002-03-13
ZA200301475B (en) 2004-05-24
CN1449288A (zh) 2003-10-15
NO20030899L (no) 2003-04-28
WO2002017894A2 (en) 2002-03-07
BR0113555A (pt) 2003-07-22
PL365582A1 (en) 2005-01-10
US20040009963A1 (en) 2004-01-15
SK2302003A3 (en) 2003-08-05
HUP0303755A2 (hu) 2004-04-28
NO20030899D0 (no) 2003-02-26
AP2003002753A0 (en) 2003-06-30
PE20020387A1 (es) 2002-06-24
JP2004507494A (ja) 2004-03-11
ECSP034487A (es) 2003-03-31
OA12370A (en) 2004-03-19
MXPA03001752A (es) 2003-06-04
EA200300152A1 (ru) 2003-08-28

Similar Documents

Publication Publication Date Title
AR030516A1 (es) Uso de una combinacion de salmeterol y fluticasona
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
CY2016031I2 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
AR028238A1 (es) Tratamiento para el tabaco
LTC1562603I2 (lt) Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
CO5140098A1 (es) Combinaciones de un agonista de betra-2 y un esteroide, su uso para tratamiento de enfermedades inflamatorias u obstructivas de las vias aereas
AR028423A1 (es) Inhibidores de la replicacion del hiv
ES2178943A1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
EP2019825A4 (en) HEMMER OF THE REPRODUCTION OF HUMAN IMMUNE DEFICIENCY VIRUSES
ATE486840T1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
ATE276244T1 (de) Replikationsinhibitoren des respiratorischen synzytialvirus
BR0111694B1 (pt) composição de limpeza aquosa para todos os propósitos.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
MXPA03006014A (es) Dentifrico de componente dual para reducir los olores de la boca.
DE60105369D1 (de) Wegwerfhöschen
EP1594435A4 (en) INHIBITION OF HIV-1 REPLICATION BY TREATMENT OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN
PT1268482E (pt) Piranoindois para o tratamento de glaucoma
UY26912A1 (es) Uso de una combinación de salmeterol y fluticasona
PA8800601A1 (es) Productos quimioterapeuticos cristalinos
PT1865966E (pt) Uso de fármacos anti-inflamatórios não esteróides por inalação no tratamento de bronquite aguda e crónica
PT1276495E (pt) Utilizacao de tensioactivo pulmonar recombinante para o tratamento precoce de doencas pulmonares agudas
IT1318516B1 (it) Derivati 2-amminotetralinici otticamente attivi, procedimenti per laloro preparazione e impiego terapeutico delle corrispondenti
DK1411936T3 (da) Anvendelse af thiazolderivater i fremstillingen af et medikament til behandling af kronisk obstruktiv lungesygdom
ATA20092000A (de) Ophthalmologisches kurzkohärenz interferometer

Legal Events

Date Code Title Description
FB Suspension of granting procedure